A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease

Exclusion Criteria

• •Presence of another inherited neurological disease, e.g., other forms of CLN or seizures unrelated to CLN2 disease (patients with febrile seizures may be eligible)
• •Presence of another neurological illness that may have caused cognitive decline (e.g., trauma, meningitis, hemorrhage) or interference with disease rating (autism) before Screening
• •Presence of percutaneous feeding tube placement prior to enrollment
• •Has received stem cell, gene therapy, or ERT
• •Presence of contraindications for neurosurgery (e.g., congenital heart disease, severe respiratory impairment, or clotting abnormalities)
• •Presence of contraindications for MRI scans (e.g., cardiac pacemaker, metal fragment or chip in the eye, aneurysm clip in the brain)
• •Episode of generalized motor status epilepticus within 4 weeks before the First Dose visit
• •Severe infection (e.g., pneumonia, pyelonephritis, or meningitis) within 4 weeks before the First Dose visit (enrollment may be postponed)
• •Presence of ventricular abnormality (hydrocephalus, malformation)
• •Presence of ventricular shunt
• •Has known hypersensitivity to any of the components of BMN 190
• •Has received any investigational mediation within 30 days before the first infusion of study drug or is scheduled to receive any investigational drug other than BMN 190 during the course of the study
• •Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with the protocol required testing or procedures or compromise the subject's well being, safety, or clinical interpretability
• •Pregnancy any time during the study; a female subject judged by the investigator to be of childbearing potential will be tested for pregnancy